Codexis (LTS:0I0X) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0I0X Codexis Inc LTS:0I0X
59 GF Score
Price $2.35
GF Value $2.69
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Codexis Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LTS:0I0X
59GF Score
Codexis Inc LTS:0I0X
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Codexis (LTS:0I0X) Overvalued in 2026?

Based on GuruFocus' analysis, Codexis stock appears to be undervalued. The current stock price of $2.35 is trading 12.6% below its estimated GF Value™ of $2.69. GuruFocus considers Codexis to be Modestly Undervalued.

Key valuation signals for LTS:0I0X:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $2.69 vs. price of $2.35 (12.6% below fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the LTS:0I0X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Codexis Business Description

Other Exchanges CDXS:USA4QK:Germany
Address 200 Penobscot Drive, Redwood City, CA, USA, 94063
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
59GF Score

Get the complete analysis for LTS:0I0X

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.35
Price
$2.69
GF Value